"Philips sold Ferrari and then went on to buy a 19% stake in a Dutch healthcare company, with a P ratio around 20 and some dividend yield. Although I'm not a fan of healthcare, the valuation from the Dutch market appears fairly valued, making it a potential candidate to add value to a portfolio."
This commentary focuses on Philips' strategic move in the healthcare sector, suggesting that despite personal reservations about the sector, the pricing seems fair and could offer value in a diversified portfolio.
EXOR, RACE, CNH, STLA, PHIA Stocks!
Value Investing with Sven Carlin, Ph.D.
November 12, 2025
Company Opinion